Economic burden of psoriasis in the United States

A systematic review of the economic burden of adult psoriasis in the United States indicates that direct costs of the condition ranged from $51.7 billion to $63.2 billion in 2013. Indirect costs ranged from $23.9 billion to $35.4 billion, while medical comorbidities were estimated to add more than $36 billion.

A systematic review of the economic burden of adult psoriasis in the United States indicates that direct costs of the condition ranged from $51.7 billion to $63.2 billion in 2013. Indirect costs ranged from $23.9 billion to $35.4 billion, while medical comorbidities were estimated to add more than $36 billion. For relief of the physical symptoms of the condition as well as their emotional health, individuals with psoriasis would pay a lifetime cost of about $11,500. The annual cost of psoriasis in the United States was about $112 billion in 2013, according to the review.